We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

266 hedge funds and large institutions have $4.57B invested in Intra-Cellular Therapies Inc. in 2022 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 93 increasing their positions, 90 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

35% more call options, than puts

Call options by funds: $33.5M | Put options by funds: $24.9M

10% more funds holding

Funds holding: 241 → 266 (+25)

3% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 90

6% less capital invested

Capital invested by funds: $4.88B → $4.57B (-$307M)

15% less funds holding in top 10

Funds holding in top 10: 13 → 11 (-2)

Holders
266
Holders Change
+25
Holders Change %
+10.37%
% of All Funds
4.48%
Holding in Top 10
11
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-15.38%
% of All Funds
0.19%
New
46
Increased
93
Reduced
90
Closed
19
Calls
$33.5M
Puts
$24.9M
Net Calls
+$8.6M
Net Calls Change
-$8.72M

Top Buyers

1
AllianceBernstein
AllianceBernstein
Tennessee
+$114M
2
Holocene Advisors
Holocene Advisors
New York
+$51.3M
3
APM
Avidity Partners Management
Texas
+$44M
4
BlackRock
BlackRock
New York
+$32.8M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$22.8M

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$154M
2
WA
Wasatch Advisors
Utah
-$118M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$35.2M
4
BGIM
Brandywine Global Investment Management
Pennsylvania
-$30.5M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$21.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAM
251
Bellevue Asset Management
Washington
$2K – – –
CA
252
Centerpoint Advisors
Massachusetts
$2K – – –
GRP
253
Global Retirement Partners
California
$2K – – –
MPWT
254
MassMutual Private Wealth & Trust
Connecticut
$2K – – –
AAP
255
Arax Advisory Partners
Colorado
$1K – – –
VCM
256
Versant Capital Management
Arizona
$1K – – –
IFAM
257
Institutional & Family Asset Management
Colorado
$1K +$567 +10 New
DFCM
258
Dark Forest Capital Management
Puerto Rico
$1K +$737 +13 New
GWS
259
Glassman Wealth Services
Virginia
$1K +$907 +16 New
Federated Hermes
260
Federated Hermes
Pennsylvania
$1K +$1.08K +19 New
BIA
261
Bell Investment Advisors
California
$1K +$1.36K +24 New
FSWA
262
Financial Synergies Wealth Advisors
Texas
$343 +$340 +6 New
MF
263
Magnetar Financial
Illinois
$298 +$63.8K +1,125 +27%
Marshall Wace
264
Marshall Wace
United Kingdom
– -$154M -2,519,764 Closed
ERSOT
265
Employees Retirement System of Texas
Texas
– -$5.97M -97,500 Closed
CCIA
266
Campbell & Co Investment Adviser
Maryland
– -$2.32M -37,863 Closed
Balyasny Asset Management
267
Balyasny Asset Management
Illinois
– -$1.96M -31,967 Closed
GL
268
Graypoint LLC
New York
– -$1.62M -26,436 Closed
BC
269
Brookfield Corp
Ontario, Canada
– -$1.56M -25,540 Closed
VCM
270
Virtue Capital Management
Tennessee
– -$1.12M -18,232 Closed
VF
271
Virtu Financial
New York
– -$1.05M -17,143 Closed
CANY
272
Caxton Associates (New York)
New York
– -$893K -14,591 Closed
TC
273
TwinBeech Capital
New York
– -$754K -12,317 Closed
MS
274
Maven Securities
Jersey
– -$546K -8,919 Closed
Cambridge Investment Research Advisors
275
Cambridge Investment Research Advisors
Iowa
– -$349K -5,701 Closed
8 9 10
11
12

ITCI Hedge Fund Activity: Q2 2022 in Review

266 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2022, worth a combined $4.57B — down 6.3% from $4.88B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ITCI positions and 19 closed out — a net gain of 27 holders — while 93 added to existing stakes and 90 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $114M. The largest seller was Marshall Wace, exiting entirely with an estimated $154M sold.

  • 266 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2022, up from 241 in Q1 2022.
  • Funds reported $4.57B of Intra-Cellular Therapies Inc. stock for Q2 2022, down 6.3% quarter-over-quarter.
  • 46 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2022 and 19 closed out, a net change of +27 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2022 was AllianceBernstein, an estimated $114M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2022 was Marshall Wace, an estimated $154M sold.

Based on aggregated 13F filings for Q2 2022.